HomeQuestion

How do you approach DOAC dose reduction for secondary prophylaxis of VTE in cancer-associated thrombosis?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What are your top takeaways from ISTH 2025?

What is your preferred treatment agent for type 1 von Willebrand patients needing minor procedures if they have a history of severe hyponatremia with DDAVP?

How do you approach deciding which patients with hemophilia B to recommend for gene therapy?

What is your approach to managing iron overload in children with transfusion-dependent beta thalassemia who have adherence challenges or toxicity with standard chelation regimens?

Where do you anticipate positioning Mim8 (denecimig) alongside existing options within your hemophilia A prophylaxis approach, assuming regulatory approval (FRONTIER2)?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.